Single-Sided Deafness and Asymmetric Hearing Loss Post-Approval Study

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of the study is to evaluate the long-term safety and effectiveness of cochlear implantation of the approved population in adults and children with single-sided deafness and asymmetric hearing loss.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: f
View:

• Five years of age or older at the time of implantation

• Unilateral profound hearing loss, as defined by a pure-tone average (500, 1000, 2000, and 4000 Hz) of 90 dB or greater in the ear to be implanted

• Sensorineural hearing loss in the ear to be implanted, as defined by an air-bone gap less than or equal to 10 dB at two or more frequencies out of 500, 1000, 2000, and 4000 Hz and a diagnosed pathology of the outer or middle ear

• Normal hearing or mild to moderate hearing loss in the non-implanted ear, as defined by a pure-tone average (500, 1000, 2000, and 4000 Hz) of 55 dB or less

• Word recognition in the ear to be implanted of 5% or less on CNC word score in quiet

• Previous experience with an appropriately-fit Contralateral Routing of Signal (CROS) hearing aid, BI-Contralateral Routing of Signal (CROS) hearing aid, bone conduction, or traditional hearing aid, as deemed appropriate by investigator

• Fluent in English

Locations
United States
Iowa
University of Iowa
RECRUITING
Iowa City
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
WITHDRAWN
Chicago
North Carolina
University of North Carolina
ACTIVE_NOT_RECRUITING
Chapel Hill
New York
New York Eye and Ear Infirmary
RECRUITING
New York
Washington
Virginia Mason Medical Center
RECRUITING
Seattle
Other Locations
Canada
Sunnybrook Health Sciences Center
RECRUITING
Toronto
Time Frame
Start Date: 2021-02-22
Estimated Completion Date: 2026-12
Participants
Target number of participants: 65
Treatments
Other: Study Procedure
Authors
Nancy Young
Related Therapeutic Areas
Sponsors
Leads: Med-El Corporation

This content was sourced from clinicaltrials.gov